Compare iShares Bitcoin Trust (IBIT) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs IDEXX Laboratories, Inc. — how do they compare? iShares Bitcoin Trust trades at $46.62 (market cap $67.31B), while IDEXX Laboratories, Inc. trades at $516.73 (market cap $40.43B). The key difference: iShares Bitcoin Trust is the larger of the two by market cap, and iShares Bitcoin Trust is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| IBIT | IDXX | |
|---|---|---|
Market Cap | $67.31B | $40.43B |
Volume | 56,154,544 | 692,164 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $766.68 |
52-Week Low | $33.29 | $504.70 |
Typical Hold Time | 40 Days | 46 Days |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $46.79, down 0.89% with bearish technical signals from oscillators and mixed moving averages. Recent news highlights significant institutional inflows, including a $196 million single-day inflow on October 1, 2026. The stock faces resistance at $47-$48 with support at $44-$46, while RSI levels suggest potential oversold conditions. Financial ratios remain undisclosed in current data.
Outlook hinges on sustained institutional interest amid volatile ETF flows, with Q3 inflows reversing prior outflows. Risks include fee structures impacting returns and market sentiment shifts. Upside potential exists if Bitcoin ETF momentum continues, but investors face exposure to crypto market volatility without direct cash flow benefits.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
